Evidence map›Paper›PMID 42401619›Full record

ArticleScientific reports2026

Programmed cell death ligand 1(PD-L1) association in metastatic and non-metastatic oral squamous cell carcinoma: clinicopathologic and immunohistochemical study.

Eman M Kamel, Doaa A M Esmaeil, Ramy A Abdelsalam, Azza A El-Sisi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eman M KamelAssistant Lecturer of Oral Pathology, Faculty of Dentistry, Mansoura University, Mansoura, Egypt.
Doaa A M EsmaeilAssociate Professor of Oral Pathology,Faculty of Dentistry, Mansoura University, Mansoura, Egypt. doaa_esmail@mans.edu.eg.ORCID 0000-0001-9054-8333
Ramy A AbdelsalamLecturer of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Azza A El-SisiProfessor of Oral Pathology, Faculty of Dentistry, Mansoura University, Mansoura, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral Squamous Cell Carcinoma (OSCC) is considered a highly immunosuppressive malignancy largely mediated by the Programmed Cell Death 1/Programmed Cell Death Ligand 1(PD-1/PD-L1) axis. The interaction between PD-L1 expressed on tumor cells and PD-1 receptors on T-cells results in T-cell dysfunction, exhaustion, and immune evasion within the tumor microenvironment. This study aimed to evaluate PD-L1 expression in primary non-metastatic OSCC, primary metastatic OSCC, and nodal metastatic OSCC, as well as to investigate its association with different available clinicopathological parameters. Immunohistochemical staining was performed to retrospectively evaluate PD-L1 expression in 30 archival paraffin-embedded OSCC specimens retrieved from the Department of Oral Pathology, Faculty of Dentistry, and the Oncology Center, Faculty of Medicine, Mansoura University. PD-L1 immunoreactivity was evaluated using a semi-quantitative scoring system based on both the staining intensity and the percentage of positively stained cells. The percentage of immunopositive cells was scored as stated: 0 (0%); 1 (< 25%); 2 (25-50%); 3 (50-75%); and 4 (> 75%). Staining intensity was graded as follows: (0 = negative); (1 = weak); (2 = moderate); and (3 = strong). A combined immunoreactivity score was calculated by adding the percentage and the intensity for each case (range 0-7). The final score was categorized as follows: 0 (negative); 1-3 (weak); 4-7 (strong). Statistical analysis was conducted to determine significant differences and correlations between PD-L1 expression and clinicopathological parameters using the Chi-square test, Monte Carlo test, one-way ANOVA, Student's t-test, and Fisher's exact test. The p-value < 0.05 was considered statistically significant. PD-L1 immunopositivity was detected in all OSCC cases (100%). A statistically significant difference was observed among the different studied groups (p < 0.001), with the strongest PD-L1 expression detected in both primary metastatic and nodal metastatic OSCC. Strong PD-L1 expression showed a significant association with patient age (p = 0.024). Additionally, a significant correlation was identified between PD-L1 expression and the depth of tumor invasion (p < 0.001). PD-L1 expression may have a potential role in tumor progression of OSCC.

Indexed as

B7-H1 AntigenCarcinoma, Squamous CellMouth NeoplasmsAdultAgedFemaleHumansImmunohistochemistryMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesB7-H1 AntigenCD274 protein, humanImmunohistochemistryMetastatic OSCCOSCCPD-L1

Identifiers

PMID42401619
PMCPMC13333018

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.